Study guide

6.4 Neurologic, Psychiatric, and Pain Management Therapeutics

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

6.4 Neurologic, Psychiatric, and Pain Management Therapeutics

Key Takeaways Explain This Topic AI

Antiseizure medications require careful matching: broad-spectrum agents (levetiracetam, lamotrigine, valproate) treat both focal and generalized seizures, while narrow-spectrum agents (carbamazepine, phenytoin) treat focal seizures and may worsen absence/myoclonic seizures.

CANMAT depression guidelines establish SSRIs, SNRIs, bupropion, mirtazapine, and vortioxetine as first-line agents; Hunter criteria define serotonin syndrome (clonus, tremor, hyperreflexia, hyperthermia).

Bipolar disorder requires mood stabilizers (lithium, divalproex, lamotrigine) or atypical antipsychotics; lithium therapeutic range is 0.6-1.2 mmol/L, with clearance reduced by NSAIDs, thiazides, and ACEi/ARBs.

Atypical antipsychotics balance metabolic risk (highest: olanzapine, clozapine) versus EPS/prolactin risk (risperidone, haloperidol); clozapine requires mandatory hematological monitoring for agranulocytosis.

Neuropathic pain is treated first-line with gabapentinoids, SNRIs (duloxetine), or TCAs; opioid stewardship mandates monitoring morphine milligram equivalents (< 50-90 MME/day) and avoiding concurrent benzodiazepines.

Last updated: August 2026

  • Neurological Pharmacotherapy
  • Epilepsy and Antiseizure Medications (ASMs)

Antiseizure medications are classified into broad-spectrum (effective for focal and generalized seizures) and narrow-spectrum (effective for focal onset seizures; potentially aggravating generalized absence or myoclonic seizures). +-------------------------------------------------------------------------+

  • | ANTISEIZURE MEDICATION SPECTRUM OF ACTIVITY |
  • +-------------------------------------------------------------------------+
  • | |
  • | BROAD-SPECTRUM (Focal + Generalized Onset): |
  • | - Levetiracetam, Lamotrigine, Valproic Acid / Divalproex, Topiramate, |
  • | Clobazam, Brivaracetam |
  • | |
  • | NARROW-SPECTRUM (Focal Onset Only): |
  • | - Carbamazepine, Oxcarbazepine, Phenytoin, Gabapentin, Pregabalin |
  • | *WARNING: Narrow-spectrum sodium channel blockers can WORSEN generalized|
  • | absence and myoclonic seizures (e.g., in Juvenile Myoclonic Epilepsy) |
  • +-------------------------------------------------------------------------+

Medication Primary Mechanism Key Pharmacokinetics & Drug Interactions Critical Safety Warnings & Monitoring

Levetiracetam ( Keppra ) Binds SV2A synaptic vesicle protein Minimal CYP metabolism; primarily renal excretion ( 66 % 66\% 66% unchanged); minimal drug-drug interactions Neuropsychiatric adverse effects (irritability, agitation, depression, psychosis); dose adjust in renal impairment

Lamotrigine ( Lamictal ) Blocks voltage-gated N a + Na^+ N a + channels Hepatic glucuronidation (UGT1A4). Valproic acid inhibits glucuronidation (doubles lamotrigine levels ⟹ \implies ⟹ halve starting dose). Enzyme inducers halve levels Stevens-Johnson Syndrome (SJS) / TEN risk ; requires very slow dose titration (e.g., 25 mg 25\text{ mg} 25 mg daily for 2 weeks, then 50 mg 50\text{ mg} 50 mg for 2 weeks)

Valproic Acid / Divalproex Blocks N a + Na^+ N a + channels, increases GABA, blocks T-type C a 2 + Ca^{2+} C a 2 + Broad CYP and UGT inhibitor ; highly protein-bound ( 90 % 90\% 90% ); therapeutic range 350 − 700 μ mol/L 350-700\text{ }\mu\text{mol/L} 350 − 700 μ mol/L ( 50 − 100 mg/L 50-100\text{ mg/L} 50 − 100 mg/L ) Severe Teratogenicity (neural tube defects, cognitive impairment; strictly avoid in childbearing potential); weight gain, alopecia, hepatotoxicity, pancreatitis, hyperammonemia

Carbamazepine ( Tegretol ) Fast voltage-gated N a + Na^+ N a + channel blocker Potent CYP3A4, CYP1A2, CYP2C9, and auto-inducer (induces own metabolism over 3-5 weeks); therapeutic range 17 − 51 μ mol/L 17-51\text{ }\mu\text{mol/L} 17 − 51 μ mol/L HLA-B*1502 screening in Asian ancestry (severe SJS/TEN); hyponatremia (SIADH-like effect); leukopenia, aplastic anemia, agranulocytosis

Phenytoin ( Dilantin ) Fast voltage-gated N a + Na^+ N a + channel blocker Zero-Order (Michaelis-Menten) Pharmacokinetics ; nonlinear saturation kinetics; therapeutic range 40 − 80 μ mol/L 40-80\text{ }\mu\text{mol/L} 40 − 80 μ mol/L ( 10 − 20 mg/L 10-20\text{ mg/L} 10 − 20 mg/L ) Gingival hyperplasia, hirsutism, peripheral neuropathy, cerebellar ataxia/nystagmus at toxic levels; CYP inducer; highly protein-bound (adjust for low albumin)

Status Epilepticus Protocol

Phase 1 (Emergent, 0-5 min): Support airway, breathing, circulation; verify blood glucose.

Phase 2 (Initial Therapy, 5-20 min): IV Lorazepam ( 4 mg 4\text{ mg} 4 mg IV over 2 min, repeated once at 5-10 min) OR IM Midazolam ( 10 mg 10\text{ mg} 10 mg IM once if no IV access).

Phase 3 (Urgent Control, 20-40 min): IV Levetiracetam ( 60 mg/kg 60\text{ mg/kg} 60 mg/kg , max 4500 mg 4500\text{ mg} 4500 mg ), IV Fosphenytoin ( 20 mg PE/kg 20\text{ mg PE/kg} 20 mg PE/kg ), or IV Sodium Valproate ( 40 mg/kg 40\text{ mg/kg} 40 mg/kg ).

Phase 4 (Refractory, > 40 min > 40\text{ min} > 40 min ): General anesthesia with IV propofol, midazolam infusion, or ketamine.

Parkinson's Disease (PD)

Levodopa/Carbidopa ( Sinemet ): Levodopa crosses the blood-brain barrier and is converted to dopamine; carbidopa inhibits peripheral DOPA decarboxylase to prevent peripheral dopamine formation and nausea. Gold standard therapy.

Motor Complications: "Wearing-off" (end-of-dose deterioration) managed by increasing dosing frequency, adding a COMT inhibitor ( Entacapone 200 mg 200\text{ mg} 200 mg with each levodopa dose; causes orange/brown urine discoloration), or adding an MAO-B inhibitor ( Rasagiline 0.5 − 1 mg 0.5-1\text{ mg} 0.5 − 1 mg daily, Selegiline ).

Peak-Dose Dyskinesias: Managed by lowering individual levodopa doses or adding Amantadine (NMDA antagonist).

Dopamine Agonists (Pramipexole, Ropinirole): Direct dopamine receptor stimulation. Adverse effects: Impulse control disorders (pathological gambling, hypersexuality, compulsive shopping), sudden sleep attacks, peripheral edema, hallucinations.

Anticholinergics (Benztropine, Trihexyphenidyl): Used for resting tremor in younger patients ( < 60 < 60 < 60 years); avoid in older adults due to confusion, memory impairment, urinary retention, and constipation.

Migraine Management

Acute Abortive Therapy:

Mild-to-Moderate: NSAIDs (Naproxen, Ibuprofen) or Acetaminophen.

Moderate-to-Severe: Triptans (5- H T 1 B / 1 D HT_{1B/1D} H T 1 B /1 D ​ receptor agonists: Sumatriptan , Rizatriptan , Zolmitriptan ). Induce cranial vasoconstriction and inhibit trigeminal calcitonin gene-related peptide (CGRP) release. Contraindications: Ischemic heart disease, prior MI, coronary vasospasm (Prinzmetal angina), stroke/TIA, uncontrolled hypertension, peripheral vascular disease. CGRP Antagonists (Gepants: Ubrogepant, Rimegepant) provide alternatives without vasoconstrictive contraindications.

Prophylactic Therapy (Indicated if ≥ 4 \ge 4 ≥ 4 headache days/month or disabling attacks):

First-Line Oral: Beta-blockers (propranolol, metoprolol), TCAs (amitriptyline), Antiseizure Drugs (topiramate, divalproex).

CGRP Monoclonal Antibodies: Erenumab (targets CGRP receptor), Fremanezumab , Galcanezumab , Eptinezumab (target CGRP ligand).

Medication-Overuse Headache (MOH): Caused by regular use of triptans/NSAIDs ≥ 10 − 15 days/month \ge 10-15\text{ days/month} ≥ 10 − 15 days/month for > 3 > 3 > 3 months.

  • Psychiatric Pharmacotherapy
  • Major Depressive Disorder (CANMAT Guidelines)

The Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines establish evidence-based first-line antidepressant therapies:

First-Line Classes:

SSRIs: Escitalopram, Citalopram, Sertraline, Fluoxetine, Paroxetine, Fluvoxamine.

SNRIs: Venlafaxine, Duloxetine, Desvenlafaxine.

NDRI: Bupropion (no sexual dysfunction, promotes weight loss; contraindicated in seizure disorders and eating disorders [anorexia/bulimia] ).

Alpha-2 Antagonist / NaSSA: Mirtazapine (potent 5 − H T 2 , 5 − H T 3 5-HT_2, 5-HT_3 5 − H T 2 ​ , 5 − H T 3 ​ , and H 1 H_1 H 1 ​ antagonism; causes sedation and increased appetite/weight gain; useful in depression with severe insomnia and anorexia).

Multimodal: Vortioxetine (SSRI + receptor modulator; improves cognitive symptoms).

Clinical Timeline: Initial improvement in sleep/appetite at 1-2 weeks; mood/energy at 2-4 weeks; full therapeutic trial requires 4 to 8 weeks at optimized doses. Continue maintenance therapy for 6 to 12 months following remission of a first episode.

Serotonin Syndrome (Hunter Criteria): Caused by excessive central serotonergic agonism (e.g., combining SSRI/SNRI with MAOIs, tramadol, linezolid, triptans, or St. John's Wort). Diagnosed by spontaneous clonus, inducible clonus with agitation/diaphoresis, ocular clonus with tremor/hyperreflexia, or hypertonia and temperature > 38 ∘ C > 38^\circ\text{C} > 3 8 ∘ C with clonus. Treat by stopping serotonergic agents, supportive care, and cyproheptadine ( 5 − H T 2 A 5-HT_{2A} 5 − H T 2 A ​ antagonist).

Antidepressant Discontinuation Syndrome (FINISH): Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances (electric shock sensations), Hyperarousal. Highest with short half-life agents (paroxetine, venlafaxine); lowest with fluoxetine.

Bipolar Disorder

Mood Stabilizers:

Lithium: Gold standard for acute mania, bipolar depression, and suicide prevention. Therapeutic Range: Acute mania 0.8 − 1.2 mmol/L 0.8-1.2\text{ mmol/L} 0.8 − 1.2 mmol/L ; Maintenance 0.6 − 0.8 mmol/L 0.6-0.8\text{ mmol/L} 0.6 − 0.8 mmol/L . Toxicity ( > 1.5 mmol/L > 1.5\text{ mmol/L} > 1.5 mmol/L ): Coarse hand tremor, ataxia, dysarthria, nausea, vomiting, confusion, seizures. Drug Interactions: Lithium clearance is decreased (toxicity risk increased) by Thiazide diuretics , ACE inhibitors / ARBs , and NSAIDs . Monitor TSH (hypothyroidism risk) and eGFR (nephrogenic diabetes insipidus / chronic kidney disease).

Divalproex / Valproic Acid: Acute mania.

Lamotrigine: First-line for Bipolar Depression maintenance ; ineffective for acute mania.

Atypical Antipsychotics: Quetiapine, Lurasidone, Olanzapine-Fluoxetine, Cariprazine for bipolar depression; Aripiprazole, Risperidone, Asenapine for acute mania.

Antipsychotic Pharmacotherapy and Adverse Effect Profiles

Antipsychotics block dopamine D 2 D_2 D 2 ​ receptors (FGAs and SGAs) and serotonin 5 − H T 2 A 5-HT_{2A} 5 − H T 2 A ​ receptors (SGAs).

Adverse Effect Category Manifestations & Mechanisms High-Risk Medications Management Strategies

Metabolic Syndrome Weight gain, insulin resistance, dyslipidemia, new-onset diabetes Clozapine , Olanzapine > Quetiapine, Risperidone Monitor baseline and routine weight, waist circumference, fasting glucose, and lipid profile; switch to Aripiprazole, Lurasidone, or Ziprasidone; add Metformin

Extrapyramidal Symptoms (EPS) - Acute Dystonia: Muscle spasms (torticollis, oculogyric crisis); - Akathisia: Subjective motor restlessness; - Parkinsonism: Bradykinesia, rigidity, tremor Haloperidol , Fluphenazine > High-dose Risperidone - Dystonia: IM/IV Benztropine or Diphenhydramine ; - Akathisia: Propranolol ( 20 − 80 mg/day 20-80\text{ mg/day} 20 − 80 mg/day ) or low-dose Lorazepam; - Parkinsonism: Dose reduction or switch to SGA

Tardive Dyskinesia (TD) Involuntary choreoathetoid movements of face, tongue, trunk (often irreversible) Long-term FGAs > SGAs Discontinue anticholinergics; switch to Clozapine or Quetiapine; add VMAT2 Inhibitor ( Deutetrabenazine , Valbenazine )

Hyperprolactinemia Galactorrhea, amenorrhea, gynecomastia, sexual dysfunction, bone loss Risperidone , Paliperidone , Haloperidol Switch to prolactin-sparing SGA (Aripiprazole, Quetiapine)

Agranulocytosis Severe neutropenia (Absolute Neutrophil Count [ A N C ] < 0.5 × 10 9 /L [ANC] < 0.5 \times 10^9\text{/L} [ A NC ] < 0.5 × 1 0 9 /L ) Clozapine Mandatory national hematological registry monitoring (CSAN in Canada): weekly CBC for 26 weeks, then biweekly for 26 weeks, then monthly

Neuroleptic Malignant Syndrome (NMS) "Lead-pipe" muscle rigidity, hyperthermia ( > 38 − 40 ∘ C > 38-40^\circ\text{C} > 38 − 4 0 ∘ C ), autonomic instability, elevated CK, leukocytosis High-potency FGAs (Haloperidol) > SGAs Discontinue antipsychotic immediately; aggressive cooling, IV hydration; administer Dantrolene (muscle relaxant) and/or Bromocriptine (dopamine agonist)

  • Pain Management and Opioid Stewardship
  • Pain Classification and First-Line Management

Nociceptive Pain (Somatic/Visceral): Responds to Acetaminophen, NSAIDs ( Naproxen preferred for lower cardiovascular risk; Celecoxib for lower GI ulceration risk; Topical Diclofenac for localized osteoarthritis), and short courses of opioids for severe acute pain.

Neuropathic Pain (Peripheral/Central): Characterized by burning, tingling, allodynia, lancinating pain. First-line therapies:

Gabapentinoids: Gabapentin ( 300 − 3600 mg/day 300-3600\text{ mg/day} 300 − 3600 mg/day ) or Pregabalin ( 150 − 600 mg/day 150-600\text{ mg/day} 150 − 600 mg/day ) — binds α 2 δ \alpha_2\delta α 2 ​ δ voltage-gated calcium channels.

SNRIs: Duloxetine ( 60 − 120 mg/day 60-120\text{ mg/day} 60 − 120 mg/day ) — enhances descending noradrenergic inhibition.

Tricyclic Antidepressants (TCAs): Amitriptyline or Nortriptyline ( 10 − 75 mg 10-75\text{ mg} 10 − 75 mg at bedtime; nortriptyline causes less orthostatic hypotension and anticholinergic sedation).

Canadian Opioid Stewardship Guidelines

Morphine Milligram Equivalent (MME) Thresholds:

Keep daily opioid doses below 50 MME/day 50\text{ MME/day} 50 MME/day for chronic non-cancer pain.

Avoid or carefully justify escalating doses above 90 MME/day 90\text{ MME/day} 90 MME/day (significantly increased risk of non-fatal and fatal overdose without clinically meaningful improvements in pain or function).

High-Risk Combinations: Never coprescribe opioids and benzodiazepines or sedating muscle relaxants due to profound synergistic respiratory depression.

Opioid-Induced Constipation (OIC): Tolerance does not develop to constipation. Prescribe a prophylactic bowel regimen containing a stimulant laxative (Senna or Bisacodyl) PLUS an osmotic laxative (PEG 3350). Docusate monotherapy is ineffective.

Opioid Use Disorder (OUD) First-Line Maintenance: Buprenorphine/Naloxone ( Suboxone ) is preferred first-line over Methadone due to its ceiling effect on respiratory depression, lower overdose risk, and milder withdrawal profile. Administer only when the patient exhibits objective mild-to-moderate opioid withdrawal (COWS score ≥ 12 − 13 \ge 12-13 ≥ 12 − 13 ) to avoid precipitating acute withdrawal.